Liver diseases are a significant cause of morbidity and mortality in the Western world and in emerging economies. According to the World Health Organization (WHO), in the European Union alone there are nearly 29 million individuals who suffer from chronic liver disease.
Given this impact on the population and the resulting healthcare costs, the CIMA Hepatology Program is working on liver tumors (hepatocarcinoma and cholangiocarcinoma), steatohepatitis and porphyria and has these general objectives:
To develop liver-protection strategies that reduce mortality in patients with acute liver failure and to improve the prognosis in complete and partial (resection) extirpation and transplants.
To identify targets and create strategies for the prevention and/or treatment of fatty liver disease (steatosis), cirrhosis, liver cancer and hepatocellular carcinoma and porphyria.
The University of Navarra has one of the world's best-known groups in basic and translational hepatology. This experience has been acquired over more than 30 years in the Department of Internal Medicine at the Clínica Universidad de Navarra and over the past two decades in what is now known as the CIMA Gene Therapy and Hepatology Area. This recognition is the result of the work of Professor Jesús Prieto and the researchers who have worked in both departments.
"Hemos identificado proteínas que pueden proteger el tejido hepático durante la lesión aguda y estamos desarrollando formas de estas proteínas que pueden convertirse en fármacos", Dr. Matías Ávila, director del programa.